Zacks: Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) Will Announce Earnings of -$0.27 Per Share

Equities analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will post earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.31). Iovance Biotherapeutics reported earnings per share of ($0.32) during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Monday, March 11th.

On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.32) to ($0.97). For the next year, analysts expect that the company will report earnings of ($1.23) per share, with EPS estimates ranging from ($1.50) to ($0.93). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Iovance Biotherapeutics.

A number of brokerages have recently weighed in on IOVA. ValuEngine lowered shares of Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 7th. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 13th. BidaskClub raised shares of Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 7th. Cowen reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a research report on Tuesday, November 6th. Finally, Robert W. Baird started coverage on shares of Iovance Biotherapeutics in a research report on Wednesday, February 6th. They set an “outperform” rating and a $29.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Iovance Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $24.29.

IOVA opened at $9.72 on Wednesday. The stock has a market capitalization of $1.20 billion, a PE ratio of -6.89 and a beta of 1.92. Iovance Biotherapeutics has a twelve month low of $7.26 and a twelve month high of $19.90.

In related news, Director Merrill A. Mcpeak bought 10,000 shares of the business’s stock in a transaction on Thursday, December 13th. The shares were bought at an average price of $9.63 per share, for a total transaction of $96,300.00. Following the completion of the purchase, the director now directly owns 456,583 shares of the company’s stock, valued at $4,396,894.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Iain D. Dukes bought 12,000 shares of the business’s stock in a transaction on Tuesday, December 18th. The stock was bought at an average price of $8.65 per share, for a total transaction of $103,800.00. Following the purchase, the director now directly owns 12,000 shares of the company’s stock, valued at $103,800. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 2,164,106 shares of company stock valued at $22,150,897. Corporate insiders own 9.90% of the company’s stock.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Iovance Biotherapeutics by 8.9% during the second quarter. BlackRock Inc. now owns 6,296,691 shares of the biotechnology company’s stock worth $80,598,000 after acquiring an additional 512,844 shares during the last quarter. Credit Suisse AG grew its stake in shares of Iovance Biotherapeutics by 51.3% during the third quarter. Credit Suisse AG now owns 1,560,825 shares of the biotechnology company’s stock worth $17,559,000 after acquiring an additional 529,511 shares during the last quarter. NF Trinity Capital Hong Kong Ltd grew its stake in shares of Iovance Biotherapeutics by 83.0% during the fourth quarter. NF Trinity Capital Hong Kong Ltd now owns 228,442 shares of the biotechnology company’s stock worth $2,022,000 after acquiring an additional 103,588 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Iovance Biotherapeutics by 8.1% during the third quarter. Vanguard Group Inc now owns 4,048,782 shares of the biotechnology company’s stock worth $45,550,000 after acquiring an additional 302,649 shares during the last quarter. Finally, Stanley Laman Group Ltd. purchased a new stake in shares of Iovance Biotherapeutics during the third quarter worth about $4,244,000. Institutional investors and hedge funds own 74.30% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: Diversification in Your Portfolio

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply